Albany Molecular at hold by Jefferies

Albany Molecular Research was rated at hold and given a price target of $11.50 by Jefferies & Co., Inc. analyst David Windley. The company reported fourth-quarter 2005 results of a 1 cent per share loss compared with Jefferies' estimate of a $0.05 gain and Street consensus of a $0.06 gain. Jefferies lowered its 2006 earnings-per-share estimate to $0.06 from $0.24, while increasing 2006 sales estimates to $170.5 million from $166 million. Shares of the Albany, N.Y., pharmaceutical company were down 22 cents, or 2.03%, at $10.63 on volume of 242,196 shares versus the three-month running average of 151,309 shares. (Nasdaq: AMRI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.